S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

CTI BioPharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
4.7% Downside
$8.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.25) to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.06 out of 5 stars

Medical Sector

932nd out of 939 stocks

Pharmaceutical Preparations Industry

435th out of 439 stocks


CTIC stock logo

About CTI BioPharma Stock (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.


CTIC Stock News Headlines

Connect Biopharma Holdings Ltd (CNTB)
Theravance Biopharma Inc TBPH
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI"
If this tech goes mainstream, it could destroy the oil and gas industry, the clean energy sector, and the billionaires who profit from it…
CTI Engineering Co Ltd (9621)
Sobi completes acquisition of CTI BioPharma Corp.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Stifel Nicolaus upgrades CTI BioPharma (CTIC) to a Hold
JMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)
SVB Securities downgrades CTI BioPharma (CTIC) to a Hold
The Latest Analyst Ratings for CTI BioPharma
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
127
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$9.00
Low Stock Price Target
$8.00
Potential Upside/Downside
-4.7%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 57)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.09M
  • Mr. David H. Kirske (Age 69)
    Exec. VP, CFO & Sec.
    Comp: $590.41k
  • Mr. James K. Fong (Age 61)
    Exec. VP & Chief Commercial Officer
    Comp: $597.3k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. Bruce K. Bennett Jr. (Age 71)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John P. Volpone
    Exec. VP & Chief of Staff
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics














CTIC Stock Analysis - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price target for 2024?

6 analysts have issued 12-month target prices for CTI BioPharma's stock. Their CTIC share price targets range from $8.00 to $9.00. On average, they expect the company's stock price to reach $8.67 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to the consensus estimate of $24.88 million. During the same period in the prior year, the company earned ($0.38) earnings per share.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

This page (NASDAQ:CTIC) was last updated on 2/23/2024 by MarketBeat.com Staff